title: Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors.
authors.affiliation: Department of Dermatology, EasternVirginia Medical School, Norfolk,VA 23507, USA.
authors.forename: Genevieve
authors.initials: G
authors.lastname: Egnatios
authors.forename: Molly Mae
authors.initials: MM
authors.lastname: Warthan
authors.forename: Robert
authors.initials: R
authors.lastname: Pariser
authors.forename: Antoinette F
authors.initials: AF
authors.lastname: Hood
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use; D000068800:Etanercept; D005260:Female; D005478:Flurandrenolone / Q000627:therapeutic use; D005528:Foot / Q000473:pathology; D006225:Hand / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D015474:Isotretinoin / Q000009:adverse effects / Q000627:therapeutic use; D007641:Keratolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011565:Psoriasis / Q000209:etiology* / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012867:Skin / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D007641:Keratolytic Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D005478:Flurandrenolone; D015474:Isotretinoin; D000068879:Adalimumab; D000068800:Etanercept; D011241:Prednisone; D008727:Methotrexate